AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02202252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of double drains
Description: Two drains will be inserted into the axilla and below the lower flap in the double drains group.
Study NCT02202252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography after removal of the drains
Description: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
Study NCT00739232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSD-016
Study NCT00739232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02612857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Dose Group 1
Description: IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
Study NCT02612857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Dose Group 2
Description: IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
Study NCT02612857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline subcutaneous injections once a week for 24 weeks.
Study NCT01782092 — intervention group
Intervention type: OTHER
Intervention: Chiropractic Adjustment
Description: Chiropractic adjustments will be administered using Activator Methods Basic protocol
Study NCT04287179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
Study NCT04287179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
Study NCT03750565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose A
Description: oral capsule/tablet, QD
Study NCT03750565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose B
Description: oral capsule/tablet, QD
Study NCT03750565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose C
Description: oral capsule/tablet, QD
Study NCT03750565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule/tablet, QD
Study NCT02300610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
Study NCT02300610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
Study NCT02300610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
Study NCT02310308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
Study NCT02310308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
Study NCT02310308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
Study NCT01289522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab IV
Description: * Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~* Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~* Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.
Study NCT01289522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: No intervention, only biopsy for translational project.
Study NCT01939912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Antiarrhythmic agent.
Study NCT00672802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo
Description: Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
Study NCT02030600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02030600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02030600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT02030600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine 80 mg/d
Description: 40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily for 42 days
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS methylphenidate HCl 54 mg/d
Description: 36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 3 mg/d
Description: 3-mg capsule once daily for 42 days
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 1 mg/d
Description: 1-mg capsule once daily for 42 days
Study NCT00880217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 10 mg/d
Description: 10-mg capsule once daily for 42 days
Study NCT00177411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone-related Protein
Description: Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
Study NCT04898881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast Human Milk
Description: Interventional drug is given to the neonates 2 minutes before the heel lance
Study NCT04898881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 24 % Sucrose
Description: 0.5 ml of sucrose given once 2 minutes prior to procedure
Study NCT04229823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video-oculography
Description: Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
Study NCT04229823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales
Description: All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
Study NCT04229823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genotyping
Description: Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
Study NCT06195085 — intervention group
Intervention type: RADIATION
Intervention: CT-guided radioactive iodine-125 seed implantation
Description: The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
Study NCT00255177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)
Description: VGX-410 tablets taken daily or twice daily for 28 days
Study NCT00255177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for VGX-410 tablets taken daily or twice daily for 28 days
Study NCT03588117 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physician-supervised nonsurgical weight management program
Description: Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
Study NCT01256307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training and educational program
Description: 8 weeks
Study NCT01256307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational program
Description: 8 weeks
Study NCT01219608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine 0.5 g/kg/day
Description: Glutamine 0.5 g/kg/day
Study NCT01219608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine 1 g/kg/day
Description: Glutamine 1 g/kg/day
Study NCT01219608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enteral Nutrition
Description: Ordinary Enteral Nutrition
Study NCT02990052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plating
Description: Open reduction and volar fixed-angle plate fixation of distal radius fracture
Study NCT02990052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Closed reduction \& casting of distal radius fracture
Study NCT00478959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid®)
Description: 25mg PO daily for 21 out of 28days per cycle
Study NCT00407511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
Study NCT02094365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176
Study NCT02094365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Study NCT03786393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ACR 1990 fibromyalgia critters
Description: ACR 1990 fibromyalgia critters
Study NCT01541748 — intervention group
Intervention type: OTHER
Intervention: Axis
Description: Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
Study NCT01675778 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydromorphone
Description: a fixed dose (1 mg) of hydromorphone will be given to the study subjects
Study NCT01110941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin
Description: S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
Study NCT01163799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept (ASP0485)
Description: Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
Study NCT01980758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastric Plication
Description: The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
Study NCT02258061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DDD-80
Description: Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
Study NCT02258061 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DDD-60
Description: Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
Study NCT02619188 — intervention group
Intervention type: OTHER
Intervention: PUQE-form inclusion
Description: PUQE-form encompassing last 24 hours completion
Study NCT02619188 — intervention group
Intervention type: OTHER
Intervention: Nutritional form inclusion
Description: Food-list form encompassing last 24 hours completion
Study NCT02619188 — intervention group
Intervention type: OTHER
Intervention: Blood sampling inclusion
Description: Measurement of biochemical nutrition marker(s); Prealbumin
Study NCT02619188 — intervention group
Intervention type: OTHER
Intervention: Intervention at discharge
Description: PUQE-form, nutritional form and Blood sampling
Study NCT03931122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)
Description: The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width.
Study NCT03482024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.
Study NCT01555775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P-CHO supplement
Description: In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
Study NCT01555775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Milk Shake
Description: The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
Study NCT00204737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 20mg x 2 weeks
Study NCT00204737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03650647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carious dentin removal
Description: Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
Study NCT03650647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious dentin removal
Description: Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
Study NCT05873738 — intervention group
Intervention type: DRUG
Intervention: Nicotine replacement
Description: Nicotine patches
Study NCT00223821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride, extended-release, individually-titrated
Description: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
Study NCT00223821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin chloride, extended-release, individually-titrated
Description: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
Study NCT00223821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Training
Description: Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
Study NCT02629302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: physiotherapy, speech therapy and occupational therapy in the presence of an animal
Study NCT02629302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard physiotherapy, speech therapy and occupational therapy
Study NCT00676143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Study NCT00676143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Study NCT03662568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state
Study NCT03662568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state
Study NCT03662568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: Administered orally ETV 0.5 mg once daily in fasted state
Study NCT03662568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Administered TDF 300 mg orally once daily in fasted state
Study NCT03318562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: 200 mg eFT508 dosed BID for 3 week cycles
Study NCT00757653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA
Description: Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
Study NCT00757653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
Description: Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
Study NCT00757653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip stem with Interloc Titanium surface + Bonemaster H.A
Description: Hip stem with Interloc Titanium surface + Bonemaster H.A
Study NCT04399447 — intervention group
Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS
Study NCT02832713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A ( BoNT-A)
Description: Intra-articular injection of BoNT-A
Study NCT02832713 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (HA)
Description: Intra-articular injection of Hyaluronic acid
Study NCT04133389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growth mindset of personality educational intervention
Description: This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
Study NCT04133389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Growth mindset of athletic ability educational intervention
Description: This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
Study NCT00706797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept (EnbrelTM)
Study NCT00706797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate